Onconetix (ONCO) Stock Price, News & Analysis

Company Overview

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Key Stats

• Today's Range: $0.93 to $1.10
• 50-Day Range: $0.94 to $7.68
• 52-Week Range: $0.88 to $270.00
• Volume: 388,192 shs
• Average Volume: 716,843 shs
• Market Capitalization: $1.09 million
• P/E Ratio: 0.08
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Onconetix Stock Analysis - MarketRank™

Onconetix scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Onconetix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Onconetix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Onconetix is 0.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of Onconetix is 0.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.81.

Price to Book Value per Share Ratio

Onconetix has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.64% of the float of Onconetix has been sold short.

Short Interest Ratio / Days to Cover

Onconetix has a short interest ratio ("days to cover") of 0.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Onconetix has recently decreased by 64.09%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Onconetix does not currently pay a dividend.

Dividend Growth

Onconetix does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Onconetix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.2 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $8,404.00 in company stock, which represents 0.7715% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Onconetix insiders have bought 5.82% more of their company's stock than they have sold. Specifically, they have bought $152,867.00 in company stock and sold $144,463.00 in company stock.

Percentage Held by Insiders

0.27% of the stock of Onconetix is held by insiders.

Percentage Held by Institutions

23.89% of the stock of Onconetix is held by institutions.

Company Calendar

• Last Earnings: 11/13/2025
• Today: 7/03/2026
• Next Earnings (Estimated): 8/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONCO
• Previous Symbol: NASDAQ:ONCO
• CIK: 1782107
• Web: www.bwbioinc.com
• Phone: 513-620-4101
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $11.40
• Trailing P/E Ratio: 0.08
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.03 million
• Net Margins: -1,316.28%
• Pretax Margin: -1,316.28%
• Return on Equity: -101.08%
• Return on Assets: -47.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.41
• Quick Ratio: 1.37

Sales & Book Value

• Annual Sales: $810 thousand
• Price / Sales: 1.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $505.29 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 1,140,000
• Free Float: 1,137,000
• Market Cap: $1.09 million
• Optionable: N/A
• Beta: 2.69